EUCTR2008-004236-20-IT进行中（未招募）不适用
PET-CT DIAGNOSIS OF CARCINOMA PROSTATICO WITH ALTERNATIVE TO FLUORODESOSSIGLUCOSIO Radio: 18F-COLINA - ND
AZIENDA OSPEDALIERA ARCISPEDALE S. MARIA NUOVA0 个研究点开始时间: 2009年3月24日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Male
入选标准
- •1. Patients with histological diagnosis of early prostate cancer, surgically treated with radical intent, which, after a month after, we have not observed the reset of PSA (> 0.2 ng / ml, but not> 2 ng / ml ).
- •2nd Patients with histological diagnosis of early prostate cancer, surgically treated with radical intent with zero PSA after 1 month, which is a documented biochemical recurrence with PSA values> 0.2 and <2 ng / ml, allowing a subsequent radiotherapy in rescue.
- •3rd Patients with histological diagnosis of prostate cancer early, to be treated with radiotherapy with radical intent, to define the Biological Target Volume
- •4th Patients with histological diagnosis of early prostate cancer treated with radiotherapy with radical intent, which, after 18 months, after reaching the nadir, the PSA shows an increase> 2 ng / ml.
- •5th Patients with histological diagnosis of early prostate cancer, already treated with radical intent with surgery or radiotherapy and / or hormonal therapy, with bone scintigraphy and / or abdominal and pelvic CT showing a situation of oligometastatizzazione, in which case the PET-CT with choline defining the actual extent of metastasis, for proper selection of patients by radiation therapy to address in order to prolong and improve the survival with no macroscopic disease.
- •6th Staging of disease highly aggressive prostate cancer (Gleason> 7). The data emerging in the literature survey PET-CT with 18F-choline appears to have in these patients a higher sensitivity than conventional all`imaging.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients outside indication
研究者
相似试验
招募中
不适用
Diagnostic Performance of PET Imaging for Prostate Specific Membrane Antigen (PSMA)Prostate cancerJPRN-UMIN000037697Osaka University Graduate School of Medicine250
进行中（未招募）
1 期
Imaging of the prostate tumors using PET/CT and PET/MRI with the ligand of the prostatic specific membrane antigene 68Ga-PSMA-11prostatic carcinoma higly suspected or its staging or restagingEUCTR2017-004128-32-CZFakultní nemocnice Plzen200
进行中（未招募）
1 期
PSMA-PET/CT for prostate cancerEUCTR2017-003461-96-BEGhent University Hospital72
尚未招募
不适用
â??Use of Gallium-68PET-CT in the Diagnosis and Follow-up of patients with Prostate Cancerâ??CTRI/2018/07/014933International Atomic Energy Agency
进行中（未招募）
1 期
18F-PSMA PET in primary prostate cancer.75 patients with the suspicion on PCa (elevated PSA and/or abnormal digital rectal exam) will receive a PSMA-PET following mpMRI. 25 patients with PIRADS 1-2 (probably benign disease), 25 patients with PIRADS 3 (equivocal disease) and 25 patients with PIRADS 4-5 (highly suspicious for malignancy) will be included in this explorative study.MedDRA version: 20.0Level: LLTClassification code 10036921Term: Prostate carcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2020-001387-28-NLRadboud University Medical Center75